Showing results (201-210 of 286) with videos related to
Sort By:
Pageof 29
The American Journal of Pathology|July 19, 2011
Pleural mesothelioma instigates tumor-associated fibroblasts to promote progression via a malignant cytokine networkQi Li, Wei Wang, Tadaaki Yamada, et al.International Journal of Oncology|August 28, 2012
Therapeutic antitumor efficacy of anti-epidermal growth factor receptor antibody, cetuximab, against malignant pleural mesotheliomaJun Kurai, Hiroki Chikumi, Kiyoshi Hashimoto, et al.Molecular Cancer Therapeutics|July 31, 2012
Combined therapy with mutant-selective EGFR inhibitor and Met kinase inhibitor for overcoming erlotinib resistance in EGFR-mutant lung cancerTakayuki Nakagawa, Shinji Takeuchi, Tadaaki Yamada, et al.Lung Cancer (Amsterdam, Netherlands)|June 20, 2024
Combination therapy with immune checkpoint inhibitors and denosumab improves clinical outcomes in non-small cell lung cancer with bone metastasesYohei Asano, Norio Yamamoto, Satoru Demura, et al.Journal of Thoracic Disease|April 16, 2026
Estimating nasal nitric oxide from measured fractional exhaled nitric oxide and nasal fractional exhaled nitric oxideMiki Abo, Yuriko Tsumaya, Takashi Ohki, et al.Proceedings of the National Academy of Sciences of the United States of America|December 12, 2013
PI3K regulates MEK/ERK signaling in breast cancer via the Rac-GEF, P-Rex1Hiromichi Ebi, Carlotta Costa, Anthony C Faber, et al.The Journal of Pathology|August 22, 2025
Characteristic miRNA profiles represent clinicopathological diversity of small cell lung cancerMasafumi Horie, Hiroshi Takumida, Hayato Koba, et al.Oncology Reports|October 30, 2020
ARHGAP29 expression may be a novel prognostic factor of cell proliferation and invasion in prostate cancerKosuke Shimizu, Hiroaki Matsumoto, Hiroshi Hirata, et al.The American Journal of Pathology|July 14, 2012
Dual inhibition of Met kinase and angiogenesis to overcome HGF-induced EGFR-TKI resistance in EGFR mutant lung cancerShinji Takeuchi, Wei Wang, Qi Li, et al.Cancer Research|November 18, 2008
Hepatocyte growth factor induces gefitinib resistance of lung adenocarcinoma with epidermal growth factor receptor-activating mutationsSeiji Yano, Wei Wang, Qi Li, et al.Pageof 29